Immunocore Holdings (IMCR) Change in Receivables (2021 - 2026)

Immunocore Holdings (IMCR) has reported Change in Receivables for 6 consecutive years, with $7.9 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Receivables rose 1048.56% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.1 million (up 203.01% YoY) and the FY2025 annual result came in at $7.3 million, down 40.59% from the prior year.
• Change in Receivables improved to $7.9 million in Q1 2026 per IMCR's latest filing, from -$2.0 million in the prior quarter.
• Over the last five years, Change in Receivables for IMCR reached as high as $10.2 million in Q4 2023 and fell as low as -$8.3 million in Q4 2022.
• A 5-year average of $2.1 million and a median of $2.7 million in 2024 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2025 — Change in Receivables slumped 253.98% — and 2026, when it jumped 1048.56%.
• Year by year, Change in Receivables stood at -$8.3 million in 2022, then jumped by 223.31% to $10.2 million in 2023, then sank by 87.33% to $1.3 million in 2024, then sank by 253.98% to -$2.0 million in 2025, then jumped by 497.69% to $7.9 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $7.9 million, -$2.0 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.